Zoetis Inc. (NYSE:ZTS) Stock Holdings Increased by Soros Capital Management LLC

Soros Capital Management LLC raised its stake in Zoetis Inc. (NYSE:ZTS) by 82.4% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 13,211 shares of the company’s stock after buying an additional 5,970 shares during the quarter. Soros Capital Management LLC’s holdings in Zoetis were worth $2,152,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also modified their holdings of the stock. Callahan Advisors LLC grew its stake in shares of Zoetis by 90.4% in the 4th quarter. Callahan Advisors LLC now owns 13,105 shares of the company’s stock valued at $2,135,000 after buying an additional 6,221 shares in the last quarter. CIBC Asset Management Inc raised its holdings in Zoetis by 24.1% during the fourth quarter. CIBC Asset Management Inc now owns 237,369 shares of the company’s stock valued at $38,617,000 after buying an additional 46,050 shares in the last quarter. Pensionfund Sabic boosted its stake in shares of Zoetis by 55.6% during the 4th quarter. Pensionfund Sabic now owns 11,200 shares of the company’s stock worth $1,825,000 after acquiring an additional 4,000 shares in the last quarter. PFW Advisors LLC acquired a new position in shares of Zoetis during the 4th quarter valued at about $1,764,000. Finally, Schroder Investment Management Group raised its stake in shares of Zoetis by 2.6% in the 4th quarter. Schroder Investment Management Group now owns 245,726 shares of the company’s stock valued at $40,036,000 after acquiring an additional 6,169 shares in the last quarter. 92.80% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of analysts have recently weighed in on ZTS shares. Piper Sandler boosted their price objective on shares of Zoetis from $200.00 to $205.00 and gave the stock an “overweight” rating in a research note on Thursday, February 27th. Barclays lifted their price objective on Zoetis from $242.00 to $244.00 and gave the stock an “overweight” rating in a research note on Friday, February 14th. StockNews.com upgraded Zoetis from a “hold” rating to a “buy” rating in a report on Friday, March 7th. Morgan Stanley cut their target price on shares of Zoetis from $243.00 to $238.00 and set an “overweight” rating for the company in a research note on Friday, February 14th. Finally, Stifel Nicolaus dropped their price objective on shares of Zoetis from $180.00 to $165.00 and set a “buy” rating on the stock in a report on Monday, April 14th. One analyst has rated the stock with a hold rating, ten have issued a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, the company has an average rating of “Buy” and an average price target of $214.40.

Zoetis Price Performance

ZTS opened at $148.64 on Monday. The company’s 50 day simple moving average is $160.04 and its 200-day simple moving average is $169.66. Zoetis Inc. has a one year low of $139.70 and a one year high of $200.33. The company has a debt-to-equity ratio of 1.09, a current ratio of 1.75 and a quick ratio of 1.08. The stock has a market capitalization of $66.32 billion, a P/E ratio of 27.17, a price-to-earnings-growth ratio of 2.78 and a beta of 0.92.

Zoetis (NYSE:ZTS) last issued its quarterly earnings results on Thursday, February 13th. The company reported $1.40 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.37 by $0.03. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. The firm had revenue of $2.32 billion for the quarter, compared to analyst estimates of $2.30 billion. Sell-side analysts anticipate that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 3rd. Investors of record on Monday, April 21st will be paid a $0.50 dividend. This represents a $2.00 dividend on an annualized basis and a yield of 1.35%. The ex-dividend date of this dividend is Monday, April 21st. Zoetis’s dividend payout ratio (DPR) is presently 36.56%.

Insiders Place Their Bets

In related news, Director Willie M. Reed sold 1,210 shares of the firm’s stock in a transaction dated Tuesday, March 11th. The shares were sold at an average price of $166.14, for a total transaction of $201,029.40. Following the transaction, the director now directly owns 11,245 shares of the company’s stock, valued at approximately $1,868,244.30. This trade represents a 9.71 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Roxanne Lagano sold 326 shares of the stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $170.00, for a total transaction of $55,420.00. Following the transaction, the executive vice president now owns 15,781 shares in the company, valued at approximately $2,682,770. The trade was a 2.02 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 1,862 shares of company stock valued at $312,254 over the last ninety days. 0.16% of the stock is currently owned by company insiders.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.